The regional treatment of liver metastases from breast cancer

Schlomo Schneebaum*, Michael J. Walker, Donn Young, William B. Farrar, John P. Minton

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


To determine the effect of aggressive regional therapy for liver metastasis from breast cancer, we retrospectively reviewed data on 74 patients identified with liver metastases. Forty had only liver metastases. In this group of 40 patients, 18 were treated with regional therapy only, i.e., surgical resection and/or regional chemotherapy via hepatic artery or portal vein catheters whereas 22 patients had systemic chemotherapy. The two groups were comparable. The regional chemotherapy regimen was 5‐FU, Adriamycin, methotrexate, and cytoxan. Median survival (27 months) for those patients treated with regional therapy (N = 18) was significantly longer than for those (N = 22) treated with systemic therapy (5 months) (P = 0.001). Only 45% of the regional treatment group failed in the liver. Our data, although retrospective and selective, suggest that certain subgroups of breast cancer patients with metastatic liver disease may benefit from aggressive regional therapy. © Wiley‐Liss, Inc.

Original languageEnglish
Pages (from-to)26-32
Number of pages7
JournalJournal of Surgical Oncology
Issue number1
StatePublished - Jan 1994
Externally publishedYes


  • breast cancer
  • liver metastasis
  • regional chemotherapy


Dive into the research topics of 'The regional treatment of liver metastases from breast cancer'. Together they form a unique fingerprint.

Cite this